

A PIONEER CASE OF TRANSLATIONAL RESEARCH IN DRUG DISCOVERY AND DEVELOPMENT IN BRAZIL: THE IMMUNOMODULATOR P-MAPA




NELSON DURAN^{1,2}, FABIO T.M. COSTA³, SILMARA N. PENTEADO¹, ISEU NUNES¹, MARCELA DURAN²

¹Farmabrasilis-www.farmabrasilis.org.br, ²IQ-UNICAMP, ³IB-UINICAMP




www.farmabrasilis.org.br
contato@farmabrasilis.org.br

PROTEIN MAGNESIUM AMMONIUM PHOSPHOLINOLEATE-PALMITOLEATE ANHYDRIDE (P-MAPA)




Protein aggregated polymer isolated from *Aspergillus oryzae*


Farmabrasilis: Research and development strategy



P-MAPA Biological Properties



P-MAPA Scanning Electron Micrographs



P-MAPA

P-MAPA Homogenized under high pressure

P-MAPA Homogenized under high pressure

Conclusions

- The discovery and development of P-MAPA immunomodulator is a pioneer case of translational research in Brazil
- P-MAPA is one of a few compounds developed in Brazil to undergo until clinical trials
- A *bottom-up* problem oriented approach can be more effective than *top-down*
- Drug development can also be achieved in developing countries, outside big pharmaceutical companies

Support : Farmabrasilis (Brazil) - NIH (USA)

Farmabrasilis is seeking collaborators and partners for the production and distribution of new medicaments for the benefit of economically disadvantage populations and individuals affected by neglected diseases

When appropriated, our medicines can be licensed without royalties in order to allow their use by economically disadvantaged populations